University of Colorado Cancer Center NCI-Designated Comprehensive Cancer Center | Strategic Alliance Partners

The rate of pathologic complete responses with enfortumab vedotin was 36.4% among patients with muscle-invasive bladder.

An expert from the University of Colorado (UC Health) comments on ongoing clinical trials which promise to shake up the treatment paradigm of endometrial cancer.

Wells A. Messersmith, MD, co-director of the developmental therapeutics program at the University of Colorado Cancer Center, said work in this area is needed to fill the knowledge gaps in metastatic CRC, which has a 5-year survival rate of just 11%.

Karley Trautman, DNP, ANP-BC, explains her efforts to improve the rates of venous thromboembolism (VTE), as well as the rates of recurrence of VTE in the Blood Cancer and Bone Marrow Transplant program of University of Colorado Hospital.

Karley Trautman, DNP, ANP-BC, of University of Colorado Hospital explains how a quality improvement program helped them to reduce venous thromboembolism (VTE).

A navigator-designed, proactive, weekly, telephone support call to help patients with blood cancers manage their symptoms between appointments was able to significantly reduce unplanned hospitalizations at a Colorado cancer center.